Roche (SIX: RO; OTCQX: RHHBY) announced that the FDA has accepted its supplemental Biologics License Application for obinutuzumab (Gazyva/Gazyvaro) in systemic lupus erythematosus, placing the anti-CD20 antibody on track for a regulatory decision by December 2026 — and potentially making it the first therapy of its class to carry an SLE label.
The ALLEGORY trial is a Phase III, randomized, double-blind, placebo-controlled, multicenter study enrolling 303 adults with active SLE on standard therapy, with the primary endpoint of SRI-4 response at 52 weeks.
In ALLEGORY, 76.7% of patients receiving obinutuzumab plus standard therapy achieved the SRI-4 primary endpoint at 52 weeks, versus 53.5% on placebo plus standard therapy (adjusted difference 23.1%, 95% CI: 12.5–33.6; p<0.001). On key secondary measures, DORIS remission more than doubled with obinutuzumab (33.8% vs. 13.8%), as did the Lupus Low Level Disease Activity State endpoint (57.6% vs. 25.0%). Obinutuzumab also reduced BILAG-defined flares through week 52 (HR: 0.58, 95% CI: 0.40–0.82; p=0.002), and the drug met a glucocorticoid reduction endpoint requiring sustained dosing at or below 7.5 mg/day from weeks 40 to 52. No new safety signals were identified. The full dataset was published in the New England Journal of Medicine in March 2026.
Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody that depletes B cells through direct nonapoptotic cell death and enhanced Fc-mediated effector functions, including antibody-dependent cellular cytotoxicity. That mechanism distinguishes it from the two currently approved SLE biologics: belimumab (Benlysta), which inhibits B-cell survival factor BLyS/BAFF rather than killing B cells directly, and anifrolumab (Saphnelo), which blocks the type I interferon receptor. The SLE treatment landscape also includes hydroxychloroquine and chronic immunosuppressants such as mycophenolate mofetil and azathioprine as standard backbone therapy — the same backbone used in ALLEGORY. Cross-trial comparisons are limited by differences in patient populations, background therapies, and endpoint definitions, but the DORIS remission rate of 33.8% in the obinutuzumab arm is numerically higher than remission figures reported in pivotal trials for both approved biologics.
In terms of the broader context, anti-CD20 therapy has been used off-label in SLE for more than 15 years, largely driven by rituximab, yet rituximab failed two randomized controlled trials — EXPLORER in non-renal SLE and LUNAR in lupus nephritis — and carries no FDA label for either condition. Obinutuzumab's type II binding mode and glycoengineered Fc region produce more direct B-cell killing and stronger ADCC activity than rituximab, a distinction that Roche and academic investigators have cited as a plausible explanation for the divergent trial outcomes. Roche has also filed the ALLEGORY data with the European Medicines Agency. The company already holds approvals for obinutuzumab in lupus nephritis in the US and EU, based on the separate REGENCY trial, as well as in hematologic malignancies across approximately 100 countries.
Spot something wrong? Report an issue with this article